Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

Launched by GLOBAL COALITION FOR ADAPTIVE RESEARCH · Feb 4, 2025

Keywords

ClinConnect Summary

The Department of Defense is conducting a clinical trial to evaluate a new treatment called SLS-002 for individuals suffering from Post Traumatic Stress Disorder (PTSD). This study is designed to test the safety and effectiveness of SLS-002 in a controlled environment, meaning that some participants will receive the treatment while others will receive a placebo (a non-active substance). The trial is part of a larger research effort to find better ways to help people with PTSD.

To be eligible for this trial, participants should be between the ages of 18 and 65 and must be able to use the study treatment, which is given as a nasal spray. They should also be willing to attend regular appointments for the first three months, where they will receive the treatment and be monitored. It's important that participants do not have certain medical conditions, such as a history of heart problems or significant weight issues, and they should not be using certain medications that could interfere with the study. Overall, this trial aims to explore new options for those struggling with PTSD, contributing to a better understanding of how to treat this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The following inclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).
• • 1. Is able to complete intranasal administration of study intervention.
• • 2. Is able to refrain from alcohol or cannabis consumption/use on dosing days.
• • 3. Is willing and able to attend dosing visits as outlined in the protocol (twice a week for the first 8 week and then once a week for Weeks 9 through 12) and agrees not to drive a car or operate machinery for 24 hours after receiving the study intervention.
• Exclusion Criteria:
• • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).
• • 1. Has a history of seizures (other than childhood febrile seizures).
• • 2. Has a body mass index \>40 or \<18 kg/m2 at Screening.
• • 3. Has known, uncontrolled hypertension or blood pressure that, in the investigator's judgment, should exclude the subject at Screening or Baseline (blood pressure may be repeated as per the site's standard operating procedures).
• • 4. Has a known history or current finding of cardiovascular disease, cerebrovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, congenital heart disease, ischemic heart disease, cardiac insufficiency, supraventricular, ventricular heart rhythm disorder, prolonged QT syndrome (ie, QTcF \>450 msec for males and \>470 msec for females) or associated risk factors (ie, hypokalemia, family history of long QT syndrome), syncope, cardiac conduction problems (eg, clinically significant heart block), exercise-related cardiac events including syncope and pre-syncope, clinically significant bradycardia, or other serious cardiac problems.
• • 5. Has a concurrent chronic or acute illness, or other condition (eg, narcolepsy, uncontrolled hyper- or hypothyroidism) that might confound the results of safety assessments conducted in the study.
• • 6. Has any medical condition that could interfere with the absorption of intranasal ketamine (eg, nasal polyps, clinically significant deviated septum \[corrected or persistent\], or other physical abnormalities of the nose).
• • 7. Has a history of interstitial or ulcerative cystitis, overactive bladder, painful bladder
• • 8. syndrome, chronic pelvic pain, frequent recurrent urinary tract infections, autoimmune disease, active urinary tract infection, history of prostate cancer, bladder cancer or bladder
• • a. surgery, or symptoms suggestive of these disorders (eg, high urinary frequency, persistent urge to urinate).
• • 9. Has any history of using ketamine or esketamine. Note previous use of ketamine for anesthesia is allowed.
• • 10. Has known or suspected intolerance or hypersensitivity to the study intervention(s), closely related compounds, or any ingredients.
• • 11. Does not meet or is not willing to comply with the requirements listed in protocol related to prohibited and restricted medications and therapies, as well as required washout periods prior to participation. Prohibited medications and therapies include, but are not limited to, monoamine oxidase inhibitors (MAOIs), chronic/frequent use of opioids or drugs with activity at the opioid receptor, psychostimulants, mood stabilizers/anticonvulsants, antipsychotics, or any medication/therapy that might confound the results of safety assessments conducted in the study. Subjects who have received any of these prohibited medications within 30 days of Screening are excluded from the study. Potent CYP 3A4 inhibitors, including nefazodone and fluvoxamine, are not permitted within 1 week of first dose and until at least 1 day after the last dose. Potent CYP 3A4 inducers, including a. St. John's wort, are not permitted within 30 days of first dose and until at least 1 day after the last dose.